Pulmonary arterial hypertension (PAH), which is clinically characterized by a sustained elevation in mean pulmonary artery pressure leading to significant morbidity and mortality, is caused by intense remodeling of small pulmonary arteries by endothelial and smooth muscle proliferation. Genetic studies in familial PAH (FPAH) have revealed heterozygous germline mutations in the bone morphogenetic protein type II receptor (BMPR2), a receptor for the transforming growth factor (TGF)-b/BMP superfamily. In this study, we conducted mutation screening in the promoter region and the entire coding regions as well as the intron/exon boundaries of the BMPR2 gene in 20 Chinese patients with either idiopathic or FPAH. All novel detected mutations were excluded by their presence in a panel of 200 chromosomes from normal individuals. A novel mutation, G-669A, in the promoter sequence of the BMPR2 gene was identified in one patient with FPAH, and no exonic mutations were detected in the proband. This mutation abolished a potential specificity protein 3 (sp3) transcription factor-binding site, and a dual luciferase assay showed that the promoter carrying the À669A allele had significantly decreased transcriptional activity compared with À669G allele. Of the other 19 patients, three novel heterozygous exonic mutations were identified: a frame shift mutation with deletion of TG at the nucleotide position 608-609 in exon 5 (Leu203fsX15), a nonsense mutation at the nucleotide position 292 in exon 3 (Glu98X) and a missense single nucleotide substitution in exon 12 (Ser863Asn).
Introduction
Pulmonary arterial hypertension (PAH) is characterized by widespread obstruction and obliteration of the small pulmonary arteries with an estimated incidence of 1 -2 per million cases per year, and a median survival from diagnosis of only 2.8 years. 1 The arterial obstruction and obliteration cause a sustained elevation of pulmonary artery pressure and lead to right-heart failure with exercise limitation, palpitations, syncope and death. 2 The development of PAH mainly affects small pulmonary arteries in which there is intense remodeling resulting in intimal thickening and medial hypertrophy because of an abnormal proliferation of smooth muscle and endothelial cells. 3, 4 The most significant advance in understanding the pathogenesis of PAH has been the demonstration of germline mutations in the familial form of this disease that have been mapped to a single locus designated PPH1 (OMIM 178600) on chromosome 2q31 -32. 5 Subsequently, two independent groups identied heterozygous germline mutations in the gene encoding the bone morphogenetic protein type II receptor (BMPR2), a member of the transforming growth factor (TGF)-b superfamily of transmembrane serine/threonine kinase receptors, in patients with familial PAH (FPAH). 6, 7 Although mutations in the BMPR2 gene (OMIM 600799) are present in more than approximately 70% of FPAH and up to 40% of patients with apparently sporadic idiopathic PAH (IPAH), 8 -10 no mutations in the promoter regions of the BMPR2 gene have been found to be associated with PAH. In this study, we reported, for the first time, a novel mutation G-669A in the promoter sequences and three novel exonic mutations of the BMPR2 in Chinese patients with PAH.
Materials and methods

Patients' data
Twenty unrelated patients with either IPAH or FPAH were enrolled. At the time of enrollment, the patients provided written informed consent according to a protocol approved by the institutional review board of the Cardiovascular Institute, Chinese Academy of Medical Sciences. Blood samples, detailed family histories and medical records were obtained. A review of complete medical records confirmed the diagnosis of IPAH or FPAH according to consensus standards. 11 In brief, the diagnosis of IPAH required that a consultant with expertize in pulmonary vascular disease confirm the following: (1) mean pulmonary arterial pressure (PAP) 425 mm Hg, with a pulmonary capillary wedge pressure r15 mm Hg, both measured at rest by right heart catheterization and (2) the exclusion of other disorders known to cause pulmonary hypertension by clinical evaluation and objective tests, for example, ventilation and perfusion lung scans to exclude pulmonary embolism, contrast echocardiography and/or measurements of oxygen saturation during cardiac catheterization to exclude intracardiac shunting, and echocardiography and cardiac catheterization to exclude left heart disease.
Mutation detection
Genomic DNA was isolated from peripheral blood leukocytes with a standard salting-out protocol. The 2022 bp length sequences upstream of the initiation codon (nucleotides are numbered according to the DNA sequence, with the adenosine of the initiation codon assigned position þ 1) were divided into four fragments for amplification. PCR primers were designed to amplify the coding regions and the intron/exon boundaries of the BMPR2 gene in the 20 patients and a panel of 200 chromosomes from normal blood donors who were from the same ethnic/regional origin and age and gender matched with the patients. The sequences of each set of primers and PCR conditions are described in Table 1 . The PCR products were purified and analyzed by direct sequencing using an ABI 3730 (Applied Biosystems, CA, USA). All novel detected mutations were excluded by their presence in a panel of 200 chromosomes from normal blood donors.
Construction of luciferase reporter plasmids
Two 300 bp fragments, which carry the À669G and À669A allele, respectively, were amplified from the BMPR2 gene promoter region with specific primers (forward primer: 5 0 -GCAGCCTCTCACACCCACT and reverse primer: 5 0 -GGCAGCCCTAGTCGCATC). The PCR products which carry À669G and À669A allele were purified and cloned into the pGL3 basic vector fused with a luciferase reporter gene (Promega, Madison, WI, USA), generating two luciferase reporter constructs: pGL3-BMPR2-wild (carrying the À669G allele) and pGL3-BMPR2-mut (carrying the À669A allele). The two luciferase reporter constructs were sequenced to confirm the integrity and the presence of the desired mutation in the constructs. The pGL3 basic vector containing no promoter element was used as negative control and the pGL3 promoter vector fused with SV40 promoter element was used as positive control.
Cell culture
Human pulmonary artery endothelial cells (Cascade Biologics, Portland, OR, USA) were cultured in medium 200 (Cascade Biologics) supplemented with low serum growth supplement (Cascade Biologics). Human pulmonary artery smooth muscle cells (Cascade Biologics) were cultured in medium 231 (Cascade Biologics) supplemented with smooth muscle differentiation supplement (Cascade Biologics). The two cell cultures were supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA), 100 mg/ml penicillin, 100 mg/ml streptomycin, and kept in an atmosphere of 95% air, 5% CO 2 in a 371C humidified incubator.
Transfection and luciferase assay
Human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells were cultured in 12-well plates. The cells were transfected transiently with the pGL3-BMPR2-wild and pGL3-BMPR2-mut vectors using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 48 h, cell lysates were prepared with the Dual-Luciferase reporter assay system (Promega, Madison, WI, USA), and both Firefly and Renilla luciferase activities were measured in a Veritas Microplate Luminometer (Turner, Sunnyvale, CA, USA). The transfection efficiency was normalized according to the Renilla luciferase activity. Each transfection was carried out in quintuplicate and repeated three times.
Statistical analysis
All data were expressed as mean ± SD. Differences between groups were examined for statistical significance using Student's t-test. A P-value o0.05 denoted the presence of a statistically significant difference.
Results
Genetic findings
To detect variants presenting in the promoter region of the BMPR2 gene that potentially regulate the level of gene transcription, the 2022 bp length sequence upstream of the initiation codon was amplified in 20 IPAH or FPAH patients. Direct sequencing of the PCR products revealed that one patient with FPAH carried a novel heterozygous substitution mutation G-669A in the promoter region of the BMPR2 gene and no other mutations were found in any of the 13 exons in the proband (Figures 1 and 2 ). The other 19 PAH patients and the panel of 200 chromosomes from normal individuals were found not to harbor this mutation. Of the other 19 patients, three novel heterozygous exonic mutations were identified: a frame shift mutation with deletion of TG at the nucleotide position 608 -609 in exon 5 (Leu203fsX15), a nonsense mutation at the nucleotide position 292 in exon 3 (Glu98X) and a missense single nucleotide substitution in exon 12 (Ser863Asn). Moreover, only one mutation, Cys66Arg, in exon 2 was found to be one of the more than 140 previously reported mutations in this study (Table 2 ). Figures 1 and 2 show the pedigree of the proband (II-2) carrying the G-669A mutation. The proband was a 38-year-old female who was diagnosed at the age of 36 with dyspnea on exertion, hemoptysis and severe PAH. Echocardiography showed an enlarged right atrium (RA) and BMPR2 promoter carrying the -669A allele has decreased transcription activity compared with the À669G allele To verify the effect of the variants À669A and À669G on the transcriptional activity of the BMPR2 gene, two luciferase reporter vectors, which contain À669A allele or À669G allele, were constructed. Human pulmonary artery endothelial cells and human pulmonary artery smooth muscle cells were transiently transfected with the two vectors and luciferase activities were measured. The results showed that the BMPR2 promoter carrying the À669A allele showed significantly decreased transcriptional activity compared with that carrying the À669G allele in human pulmonary artery endothelial cells (Figure 3a ) and in human pulmonary artery smooth muscle cells (Figure 3b ).
Clinical findings
Identification of putative transcription factor-binding sites affected by the À669G and À669A alleles of BMPR2 gene Using the MAPPER Search Engine, 12 we identified a putative transcription factor-binding site affected by the À669G and À669A alleles. Figure 4b shows that the BMPR2 promoter carrying the À669G contains a consensusbinding site for specificity protein 3 (sp3) transcription factor. G-669A mutation abolishes the sp3-binding site (Figure 4a ). This change (À669G4A) altered the highly conserved G base in the sp3-binding site (Figure 4c ).
Discussion
This is the first report that a mutation in the promoter sequence of the BMPR2 gene is associated with FPAH. In earlier studies, extensive analyses of the BMPR2 gene have been conducted in patients with FPAH and IPAH from a wide range of ethnic groups. Recently, two novel missense mutations of BMPR2 gene have been identified in two Chinese families with PAH. 13, 14 Mutations of BMPR2 gene have been detected in up to 70% of recognized FPAH cases, whereas in IPAH, the reported mutation detection rate ranges from 11 to 40%. 8 -10 All the defects of BMPR2 gene identified in patients, which include all major mutation classes, with single nucleotide substitutions resulting in nonsense, 6 -10,15 -20 missense, BMPR2 mutations lead to a loss of signaling through Smad1/5 in cells and animal models. 25, 36 Thus, failure of BMP signaling through Smad1/5 in the vasculature can increase TGF-b/Smad2/3 signaling, which highlights the potential importance of a loss of Smad1/5 signaling as cause of pulmonary vascular remodeling in patients with genetic PAH. In our study, the mutation À669A in the promoter sequence of BMPR2 gene showed decreased transcriptional activity and may downregulate the expression of BMPR2 and weaken Smad1/5 signaling, similarly to BMPR2 coding region mutations.
We performed a computer analysis of the 300 bp promoter sequence that carries the À669G allele using CpG Island Searcher (http://www.uscnorris.com/cpgislands2/cpg.aspx). The result showed that this promoter region is a potential CpG Island. Methylation of CpG sites within the promoters of genes can lead to their silencing, and a feature found in a number of human cancers (for example, the silencing of tumor suppressor genes). In contrast, the demethylation of CpG sites has been associated with the overexpression of oncogenes within cancer cells. The À669G allele changed to À669A allele in the 300 bp promoter region of BMPR2 gene might have abolished a potential CpG site and resulted in its demethylation. This demethylation might cause an upregulation of the transcriptional activity of the BMPR2 gene. However, in our study, we found that the transcriptional activity of the BMPR2 promoter sequence carrying À669A allele decreased significantly compared with À669G allele in luciferase activity assay experiments; therefore, we deduced that this potential CpG site might not be functional. Searching in the MAPPER transcription factor database, 12 a potential sp3 transcription factor-binding site was identified in the BMPR2 promoter sequence carrying the À669G allele, which is abolished by the G-669A mutation. This was of interest because sp3 is a well-known transcription factor with important regulatory effects on various cellular and viral promoters. The sp family of transcription factors binds and acts through GC boxes to regulate gene expression and is recognizable by a DNA-binding domain formed from three conserved Cys2His2 zinc ngers. 37 Within this family, sp3 and sp1 are ubiquitously expressed in mammalian cells, and sp3 is structurally similar to sp1, with similar affinities for the sp1-binding site, and participates in regulating the expression of genes involved in almost all cellular processes. 38 Sp3 has been shown to act as a transcriptional activator similar to sp1 in many studies. 39 -41 Our results showed that the À669A mutant decreased luciferase transcriptional activity and had an abolished sp3 transcription factor-binding site. This suggests that sp3 may play an important role in the transcriptional regulation of BMPR2 gene. The BMPR2 gene consists of 13 exons. The mature protein harbors four discrete functional domains, including an extracellular ligand-binding domain encoded by exons 1 -3, a transmembrane domain generated by exon 4, a serine/threonine kinase domain from exon 5 -11 and a very large intracellular C-terminal domain of unknown function from exons 12 and 13. 16 This large C-terminal domain is present only in BMPR2 within the TGF-b receptor superfamily. More than 140 distinct mutations of BMPR2 gene have been identified in patients with PAH from a wide range of ethnic groups. 8 In this study, we identified three novel exonic mutations of the BMPR2 gene in the Chinese PAH patients (Table 2) , including a frame shift mutation in exon 5 (Leu203fsX15), a nonsense mutation in exon 3 (Glu98X) and a missense mutation in exon 12 (Ser863Asn). These disease-causing mutations are predicted to affect different domains of the BMPR2 protein and mutations within different regions may vary in their impact on disease initiation and progression. Only one mutation (Cys66Arg) of more than 140 mutations reported earlier has been found in Chinese PAH patients in this study. The ethnic group difference may be a potential explanation. It is well known that nonsense, missense, splice site mutations and small insertions or deletions in the genes can lead to the expression of defective protein products, which are often responsible for a hereditary disease. In our study, we have reported four novel mutations of the BMPR2 gene in Chinese patients with PAH. This posed some interesting questions, such as whether the disease can be caused by the reduced level of mRNA expression and further explorations in the future may provide us a complete picture of the role of BMPR2 in the etiology of PAH
